Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
As posted on ClinicalTrials.gov (NCT05768945), updated at source Nov 10, 2025. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.
| Measure | Semaglutiden=7,129 | DPP4 Inhibitorsn=7,129 |
|---|---|---|
| Analysis 1 | 4.40(2.27 to 7.68) | 6.06(3.70 to 9.36) |
| Analysis 2 | 4.69(1.28 to 12.02) | 6.71(2.70 to 13.83) |
| Analysis 3 | 2.80(0.34 to 10.13) | 10.24(6.96 to 14.54) |
| Analysis 4 | 0.37(0.01 to 2.04) | 0.61(0.07 to 2.19) |
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Please see https://drive.google.com/drive/folders/1VRjPaaelXFyBbA5gV6pwB\_ijSIMyIJ4N?usp=share\_link or Appendix A(https://drive.google.com/drive/folders/1OgKQlxsJi9UWRDd3Kbaux\_8adngoSnZY?usp=sharing) for full code and algorithm definitions. Medicare timeframe: 2008 to 2019 (end of data availability). Inclusion Criteria: * 1\. Aged \>/= 65 years on the index date * 2\. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date * 3\. Diagnosis code for type 2 diabetes measured 365 days prior to drug initiation Exclusion Criteria: * 1\. Prior history of dementia measured anytime prior to cohort entry date * 2\. Prior history of nursing home admission in the 365 days prior to the cohort entry date * 3\. Prior use of any GLP receptor agonists (semaglutide, exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide) or DPP4 inhibitors * 4\. Prior use of Semaglutide or DPP4 inhibitors concomitantly on index date
Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.